Uncategorized
Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapies to Overcome Limitations of Current Treatments
PHILADELPHIA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a leading life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. Initial